Aerovate Therapeutics, Inc. (AVTE) Misses Q2 EPS by 4c
Tweet
Share
E-mailGet Alerts AVTE Hot Sheet
Join SI Premium – FREE
Aerovate Therapeutics, Inc. (NASDAQ: AVTE) reported Q2 EPS of ($0.49), $0.04 worse than the analyst estimate of ($0.45).
For earnings history and earnings-related data on Aerovate Therapeutics, Inc. (AVTE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Klarna shares tumble on weak full-year revenue guidance
- Benchmark Reiterates Speculative Buy Rating on Nephros (NEPH) Following Strong Q2 Results
- Terra Innovatum Global N.V. (NKLR) Misses Q2 EPS by 12c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
